Anne Whitaker
Member of the board of directors
Nationality: American | Year of Birth: 1968
Anne Whitaker has been a member of the board since April 2026. She is a member of the compensation committee and a member of the corporate governance & nomination committee. She is independent in accordance with the Swiss Code of Best Practice for Corporate Governance.
Ms. Whitaker started her career as a pharmaceutical sales representative, taking over roles of increasing seniority and responsibility, including Vice President and Business Unit Head of the Cardiovascular, Metabolic, and Urology Business Division as well as Senior Vice President of Leadership and Organization Development for GlaxoSmithKline. Thereafter she served as president of North America Pharmaceuticals at Sanofi Aventis US LLC, as president and chief executive officer of Synta Pharmaceuticals Corporation, as executive vice president and group company chairwoman at Bausch Health Companies, Inc. (formerly Valeant Pharmaceuticals International, Inc.), as CEO and chairwoman of Aerami Therapeutics Holdings, Inc. (formerly Dance Biopharm Holdings, Inc.) and as President and CEO of Novoclem Therapeutics Inc.
Anne Whitaker is currently serving on the boards of Icon Plc., Bespak Ltd., Trinity Life Sciences, Alkermes Plc. and QurAlis Corporation (chairwoman). She is also an advisor (operating partner) at NewVale Capital LLC.
Ms. Whitaker holds a degree (BS) in chemistry from the University of North Alabama.